Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: A randomized study

详细信息    查看全文

• 作者：Virendra Singh¹ ; ^{virendrasingh100@hotmail.com} ; Souvik Ghosh¹ ; Baljinder Singh² ; Pradeep Kumar² ; Navneet Sharma³ ; Ashish Bhalla³ ; A.K. Sharma¹ ; N.S. Choudhary¹ ; Yogesh Chawla¹ ; C.K. Nain⁴
• 关键词：Ascites ; Renal dysfunction ; Splanchnic vasodilatation ; Vasopressor
• 刊名：Journal of Hepatology
• 出版年：2012
• 出版时间：June, 2012
• 年：2012
• 卷：56
• 期：6
• 页码：1293-1298
• 全文大小：1004 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Background & Aims

Various vasoconstrictors are useful in the management of hepatorenal syndrome (HRS). Terlipressin is the drug of choice; however, it is expensive. In this study, we evaluated safety and efficacy of terlipressin and noradrenaline in the treatment of HRS.

Methods

Forty-six patients with HRS type 1 were managed with terlipressin (group A, N = 23) or noradrenaline (Group B, N = 23) with albumin in a randomized controlled trial at a tertiary center.

Results

HRS reversal could be achieved in 9 (39.1 % ) patients in group A and 10 (43.4 % ) patients in group B (p = 0.764). Univariate analysis showed baseline Child Turcotte Pugh score (CTP), model of end stage liver disease (MELD), urine output on day 1(D1), albumin, and mean arterial pressure (MAP) were associated with response. However, on multivariate analysis only CTP score was associated with response. Fourteen patients in group A and 12 in group B died at day 15 (p >0.05). Noradrenaline was less expensive than terlipressin (p <0.05). No major adverse effects were seen.

Conclusions

The results of this randomized study suggest that noradrenaline is as safe and effective as terlipressin, but less expensive in the treatment of HRS and baseline CTP score is predictive of response.